Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

OncoImmunology

卷:7

Sun Wook Kim¹  Myung-Ju Ahn¹  Tae Hyuk Kim¹  Jae Hoon Chung¹  Keunchil Park¹  Hosu Kim¹  Hye In Kim¹  Young Nam Kim¹  So Young Park¹  Se-Hoon Lee¹  Tae Yong Kim²  Young Kee Shong²  Sang-We Kim²  Mijin Kim²  Won Bae Kim²  Won Gu Kim²  Min Ji Jeon²  Dae Ho Lee² 

[1] Sungkyunkwan University School of Medicine;

[2] University of Ulsan College of Medicine;

关键词: biomarkers;    immunotherapy;    non-small cell lung cancer;    programmed cell death 1;    thyroid;   

DOI  :  10.1080/2162402X.2017.1375642

来源: DOAJ

【 摘 要 】

Purpose: Drugs that blockade interaction between programmed cell-death protein 1 (PD-1) and its ligand (PD-L1) are promising. Immune-related adverse events (irAEs) might be associated with favorable clinical outcomes, and thyroid dysfunction is one of the most common irAE. We evaluated the association of thyroid dysfunction during PD-1 blockade with the treatment efficacy in patients with non-small cell lung cancer (NSCLC). Experimental Design: A total 58 patients with stage IV NSCLC treated with PD-1 blockade were enrolled. Patients were categorized into thyroid dysfunction and euthyroid groups. Overall survival (OS) and progression-free survival (PFS) of the two groups were compared. Patients, tumor, and medication factors were adjusted using Cox proportional hazard modeling. Objective response rate (RR) and durable control rate were assessed according to the severity of thyroid dysfunction. Results: OS [median 118.0 (73.0-267.0) vs. 71.0 (28.0-160.0) days, log-rank P = 0.025] and PFS [118.0 (73.0-267.0) vs. 61.0 (28.0-130.0), log-rank P = 0.014] were longer in the thyroid dysfunction group. After adjustment, thyroid dysfunction was an independent predictive factor for favorable outcome [adjusted HR = 0.11 (95% CI) 0.01-0.92 for overall death; 0.38 (0.17-0.85) for disease progression]. The severity of thyroid dysfunction was associated with durable control rate (P for trend = 0.008). Conclusions: Thyroid dysfunction during PD-1 blockade is associated with treatment response and could provide supplementary information for immune monitoring in patients with advanced NSCLC.

【 授权许可】

Unknown